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Summary. Antigens in a particulate conformation were shown to be highly 
immunogenic n mammals. For this reason, the particle forming capacity of 
derivatives of the HIV-1 group specific ore antigen p55gag was assayed and 
compared ependent on various expression systems: recombinant bacteria, vac- 
cinia- and baculoviruses were established encoding the entire core protein p 55 
either in its authentic sequence or lacking the myristylation consensus signal. 
Moreover, p 55 gag was expressed in combination with the protease (p 55-PR) 
or with the entire polymerase (p 55-po/), respectively. Budding of 100-160nm 
p 55 core particles, resembling immature HIV-virions, was observed in the 
eucaryotic expression systems only. In comparison to the vaccinia virus driven 
expression of p 55 in mammalian cells, considerably higher yields of particulate 
core antigen were obtained by infection of Spodoptera frugiperda (sfg) insect 
cells with the recombinant Autographa californica nuclear polyhedrosis 
(AcMNPV) baculovirus. Mutation of the NH2-terminal myristylation signal 
sequence prevented budding of the immature core particles. Expression of the 
HIV p 55-PR gene construct by recombinant baculovirus resulted in complete 
processing of the p 55 gag precursor molecule in this system. The introduction 
of an artificial frameshift near the natural frameshift site resulted in constitutive 
expression of the viral protease and complete processing of p 55, both in Esch- 
erichia coli and in vaccinia virus infected cells. Interestingly, significant pro- 
cessing of p 55 resembling that of HIV infected H 9 cells could also be achieved 
in the vaccinia system by fusing the entire pol gene to the gag gene. Moreover, 
* Present adress: Mikrogen GmbH, Munich, Federal Republic of Gemaany. 
118 R. Wagner et al. 
processing was not found to be dependent on amino-terminal myristylation of 
the gag procursor molecule, which is in contrast o observations with type C 
and type D retrovirus. However, complete processing of p 55 into p 24, p 17, 
p 9 and p 6 abolished particle formation. Purified immature HIV-virus like 
particles were highly immunogenic in rabbits, leading to a strong humoral 
immune response after immunization. Empty immature p 55 gag particles rep- 
resent a noninfectious and attractive candidate for a basic vaccine component. 
Introduction 
The medical importance of HIV- 1 and HIV-2 infections accelerated the detailed 
biochemical nd immunological definition of structural nd regulatory proteins 
of lentiviruses. Intensive work focused on the molecular process leading to the 
assembly of HIV-virions as one of the key mechanisms in the life cycle of HIV. 
Increasing attention has been paid to the group specific antigens of HIV-1. The 
HIV-1 gag open reading frame encodes a 55 kDa polyprotein which is subse- 
quently processed into the mature, nonglycosylated matrix protein p 17 (MA), 
the capsid protein p 24 (CA); the nucleoprotein p 9 (NP) and a link protein p 6 
(LI) [-25, 31, 41]. Cleavage of the gag precursor to yield the mature capsid 
proteins is at least in part specified by the viral protease (PR) [2, 19, 20, 23]. 
The viral protease isencoded by the NHz-terminal region of thepol open reading 
frame which contains precursor forms necessary for viral replication. The pol 
gene products are initially synthesized asa 160 kDa gagpol fusion protein, which 
results from a ( -  1) translational frameshift occurring at a relatively low fre- 
quency in the gagpol overlapping region [14]. This polyprotein precursor mol- 
ecule may be autocatalytically processed into the 9 kDa protease (PR), the 
reverse transcriptase (RT), the integrase (IN) and mature core proteins. As for 
other etroviruses [13, 41] the NH2-termini ofboth, the 55 kDa and the 160 kDa 
precursor proteins are myristylated. 
The exact role of the myristyl-moiety and the NHz-terminus of the capsid 
presursor molecule is not clear to date, although it has been identified at the 
amino-terminus of a number of retroviral gag products 1-35, 41]. Myristylation 
of the gag precursor typically occurs cotranslationally [43] and is specified by 
the NHz-terminal glycine residue next to the methionine derived from the in- 
itiation codon [15]. Obviously, the myristic acid moiety at the amino terminus 
of p 17 is essential for the release of HIV virus particles [13]. Functions as 
membrane anchor [14] or signal for intracellular t ansport [33] have been 
suggested. As has been also shown in type C Moloney murine leukemia viruses 
(Mo-MuLV), myristylation of the HIV-1 p 55gag polyprotein precursor is es- 
sential for its membrane localization and assembly of capsid protein into discrete 
particles at the plasma membrane. Changes in the p 17 amino-terminal glycine 
of provirus clones abolish myristylation of the HIV-1 precursor proteins and 
prevent virus particle release from transfected cells. In contrast to Mo-MuLV 
and type D Mason-Pfitzer monkey virus (MPMV), processing of the p 55 capsid 
precursor is not inhibited in myristylation deficient variants of HIV-1 proviral 
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clones [9]. Several groups investigated the role of p 55 in the assembly of virus 
particles when expressed in eucaryotic cells such as yeast [19] and mammalian 
cells using plasmid vectors [37] or recombinant vaccinia virus [11, 29, 36]. 
Budding of virus-like particles has recently been shown from a baculovirus 
vector in insect cells [-3, 6]. 
Due to its group specificity and its particle forming capacity, the HIV core 
antigen is a promising candidate for vaccine development. As known from other 
systems uch as hepatitis B virus, particulate antigens are highly immunogenic 
and possess intrinsic adjuvant properties [26]. High antibody titers to p 55 
during early stages of infection, the inhibiting activity of reactive monoclonal 
antibodies in vitro [30] and the significance of core proteins in the elimination 
of infected cells by cytolytic T-cells [28] support he role of p 55 gag in future 
candidate vaccines. For this reason we conducted a detailed comparative anal- 
ysis of the particle forming capacity of the HIV-1 core antigen. Identical DNA- 
constructs containing the entire gag in its natural configuration were established 
and altered (i) into a myristylation deficient form, (i0 combined with the pro- 
tease, (iii) either in its natural configuration or in frame to p 17/p 24 and (iv) 
fused to the entire pol coding sequence. The different polypeptides were ex- 
pressed in E. eoli as well as by recombinant vaccinia- and baculoviruses in
mammalian and insect cells, respectively. The experiments reported here com- 
pare the influence ofmyristylation and protease activity on HIV-1 core expres- 
sion and particle assembly in various expression systems in order to identify 
optimal conditions for the formation of recombinant core particles. Evidence 
is presented for the induction of a core specific humoral immune response after 
immunisation of rabbits with purified core particles. 
Materials and methods 
Plasmid DNA 
A DNA clone containing HIV-1 sequences, pBH 102, was kindly provided byProf. Gallo, 
NIH, Bethesda, MD, U.S.A. The baculovirus expression vector pVL 941was provided by 
Dr. Summers, Texas A &M University, College Station, TX, U.S.A. All reported were 
propagated in Eschericha coli strain JM 109. 
Ce//s 
Green monkey kidney CV-1 cells, SW 480 colon carcinoma cells and B 143 cells were grown 
in Eagles minimal essential medium (MEM) containing 5% fetal calf serum. Spodoptera 
frugiperda (Sf9) insect ells were propagated in TC 100 medium (GIBCO/BRL, Federal 
Republic of Germany) supplemented with 10% fetal calf serum. 
Sera and monoclonal antibodies 
Production and mapping of p24 specific mouse monoclonal antibody 16/4/2 usedfor 
immunoblotting was previously described by Wolf et al. [26]. A p 17 specific mouse mono- 
clonal antibody was kindly provided byProf. Chandra, University of Frankfurt, Federal 
Republic of Germany. A rabbit serum directed against the HIV-1 protease was obtained 
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by Prof. von der Helm, Max von Pettenkofer Institute, Munich, Federal Republic of 
Germany. 
Construction of recombinant plasmids 
In order to obtain precise NHz-termini of the capsid precursor we inserted a 62 bp oligo- 
nucleotide, 
GATCCATGG GTGCGAGAGC GTCAGTATTA AGCGGGGGAG AATTAGATCG 
ATGTCGACCT GCA, 
encoding the 15 NHz-terminal amino acids of p 55gag into the Barn HI~Hind III site of the 
pUC 8 vector. The restriction sites Cla I and Sal I in the 3' position within the oligonucleotide 
were used to complete the gag reading frame by insertion of a 1694 bp Cla I/Hinc II fragment 
resulting in plasmid pUC8 p55. 
For expression of the myristylation deficient capsid precursor, we replaced the 47 bp 
Bam HI/Cla I fragment encoding the amino-terminal part of p 17 by a corresponding DNA 
fragment, 
GATTCGTGCA CGCCA TGGCT GCGAGAGCGT CAGTATTAAG CGGGGGAGAA 
TTAGAT. 
A G to C transition alters the NHz-terminal glycine residue into an alanine thereby de- 
stroying the myristylation signal sequence (pUC8 p55 M-) .  The correct sequence was ver- 
ified by double strand sequencing using a T 4 polymerase sequencing kit (BRL). 
To express p55 gag with the exact protease polypeptide (PR) without additional car- 
boxy-terminal polymerase (po/) sequences we inserted a synthetic polylinker sequence, 
AATTCGGATT CGTTGACCTG CAGTAATTAA TTAGATCTCG AGCCCGCCTA 
ATGAGCGGGC TTTTTTGAGC TCA 
into the Eco RI/Hind III restriction sites of pUC 8. This linker fragment contained stop 
codons in all reading frames (italics) and a procaryotic rho independent transcription 
termination signal (pUC 8 stop) to increase the production of recombinant proteins in E. 
coli. A 402 bp Nta IV~Bali fragment including the entire protease r ading frame was inserted 
into the Hinc II site of pUC 8 stop to yield pUC 8 PR stop. For insertion of the p 55 gag 
coding sequence, we fused the pUC8 p55 derived Barn HI/BclI fragment with the Barn HI/ 
BclI fragment of pUC 8 PRstop to create pUC8 p55PR. 
To combine the gag and the protease gene in the same open reading frame, the BglII 
restriction site of pUC8 p55 PR was opened, filled enzymatically using the Klenow fragment 
and religated, thereby creating an additional Cla I site. The resulting plasmid was called 
pUC8 p55 PR-FS. The enforced frameshift replaced the carboxy terminal 63 amino acids 
ofp 15 by the HIV-1 protease. The regular ibosomal frameshift site is located 6bp upstream 
of the generated Cla I site. 
To align both the myristylation competent and incompetent forms of the gag gene with 
the entire pol gene, we replaced the 437bp BglII/SalI fragment of pUC8p55 and of 
pUC8 p55 M-  by a 3727 bp BglII/Sal I fragment including p 15 and the complete pol gene 
to create pUC8 p55 Pol and pUC8 p55 M-  Pol. 
For production of the recombinant proteins and following characterization in E.coli, 
we subcloned the coding sequences into a NcoI/SalI digested pTRC99 ATG-vector to 
avoid expression of disturbing LacZ derived NH2-terminal sequences. 
To establish recombinant vaccinia viruses, the pUC derived gag-gene constructs were 
subcloned into the BglII/SalI digested pAvB vaccinia transfer vector [27] to create 
pAvBp 55, pAvB 55 M- ,  pAvBp 55 PR, pAvBp 55 Pol, pAvBp 55 M-  Pol and pAvBPR- 
FS. For expression by recombinant baculovirus, we subcloned two relevant inserts, encoding 
p 55 and for comparison p55 PR (Fig. 1), into the Bam HI site of the transfer vector pVL 941 
1-37]. The basic gene constructs and the expression of the polypeptides in the respective 
expression systems are summarized in Fig. 1. 
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Fig. 1. Schematic reconstruction of the p 55 and Pol coding sequence. Genomic regions, 
which were included into the basic constructs are depicted as open bars. Abbreviations of 
the plasmids and recombinant viruses, described in the text are shown on the right. Re- 
striction sites essential for subcloning are indicated (B Bam HI; N Nco I; BII BglII; S SalI; 
X Xho I; C Cla I). Mutations introduced to change functional properties of the depicted 
reading frames are indicated by an open arrow ( -  1 frame shift induced by the Klenow 
fragment at the BglII restriction site, resulting in a new Cla I site) and solid arrows (myr- 
istylation signal, Gly-Ala). Biological properties of the polyproteins such as processing of 
precursor molecules (A) and particle forming capacity (O) are indicated 
Construction of recombinant vaecinia viruses 
Transfer of the HIV-1 genes from the recombinant plasmids pAvBp 55, pAvBp 55 M- ,  
pAvBp 55 PR, pAvBp 55 PR-FS, pAvBp 55 Pol and pAvBp 55 M-  Pol into vaccinia virus 
Tien Tan (vTT) was achieved by a standard homologous recombination method using CV- 
1 cells 1-24]. The recombinant vaccinia viruses were designated as v-p 55, v-p 55 M- ,  v- 
p 55 PR, v-p 55 PR-FS, v-p 55 Pol and v-p 55 M-  Pol, respectively. 
Construction of recombinant baculovirus 
Sf9 cells were cotransfected with mixtures of infectious Autographa califonica nuclear 
polyhedrosis virus (AcMNPV) DNA and CsC1 purified [34] transfer vector DNA as 
described by Smith et al. Resultant progeny baculovirus was used to produce plaques in 
Sf9 cell monolayers. Plaques lacking polyhedrin structures were selected, purified by further 
plaque assays and used to produce virus stocks. 
Analysis of recombinant polypeptides 
IPTG induced recombinant bacteria were harvested and resuspended in lysis buffer as 
described by Sambrook et al. [34]. CV-1 cells were infected with wild type vTT or recom- 
binant vaccinia virus at 10-20pfu per cell and incubated at 37°C for 24h in serum free 
MEM. Infected cells were harvested and resuspended in boiling mix. Monolayers of Sf9 
cells were infected with wild type AcMNPV or recombinant baculovirus at  multiplicity 
of 5-10 pfu/cell and incubated at 28 °C for 1-5 days. Cells were harvested and suspended 
in the lysis buffer. Supernatant was, without concentration of the recornbinant protein, 
directly mixed with lysis buffer. Protein extracts were boiled for 5rain at 100 °C and analyzed 
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by SDS-PAGE and Western blotting [21]. Immunological detection was performed using 
monoclonal antibodies directed to p24 [44], p 17 and a pool of AIDS patient sera. 
Electron microscopy 
Infected SW 480 and Sf9 cells were harvested with a cell scraper, washed with phosphate 
buffered saline (PBS) and then fixed for 2h with 2.5% glutaraldehyde in PBS. Cells were 
washed with PBS and postfixed for 1 h with osmium tetroxide in PBS. After washing in 
PBS and in distilled water, fixed cells were stained with 1% uranyl acetate in 20% acetone 
for 30 rain. Following dehydration i a graded series of acetone cells were embedded in
Spurr's low-viscosity resin. Sections of 25 to 75 nm thickness were cut with a diamond knife 
and mounted on uncoated copper grids. The sections were poststained with 100 mmol Pb- 
citrate pH 12.6. All pictures were taken with Siemens Elmiskop 101 electron microscope. 
The magnification was calibrated with a cross line grating replica. 
Gradient sedimentation analysis 
Supernatants of Sf9 cells infected with the recombinant baculoviruses b-p55 and b-p55 PR 
were collected 5 ays p.i. from synthetic medium lacking FCS. Enrichment of core particles 
from precleared culture supernatant (3300 × g) was achieved by a Ultrasette-Filtron filter 
membrane (Satorius, Federal Republic of Germany) after the protocol of the manufacturers. 
2 ml aliquots of the concentrated material was layered onto a 12 ml 10-60% sucrose gradient 
in 10 mM phosphate buffer pH 7.5 containing 0.15 M NaC1 and run at 20,000 rpm for 2 h 
in a Kontron TFT 4t. 14 rotor. Fractions (0.7 ml) were collected and directly assayed by 
conventional Western blot analysis. The yield of recombinant gag particles was determined 
using a commercial p 24/p 55 specific antigen capture assay (Abbot). 
Reverse transcriptase assay 
Supernatants of uninfected SW 480 cells and cells infected by the recombinant vaccinia 
viruses v-p55, v-p55M-Pol and v-p55Pol (10pfu/cell) were collected 2 days p.i. and 
precleared ina Kontron A 8.24 rotor for 15 min with 8000 rpm. The supernatant was layered 
onto a 2ml 37% sucrose cushion and ultracentrifuged at 5°C for 2h at 20,000rpm in a 
Kontron TFT41.14 rotor. The supernatant was discarded and the pellet was assayed for 
RT activity in a reverse transcriptase t st using poly rA:dT and Mg ++ as described 
previously [10]. 
Results 
Basic constructs and concepts 
In order to conduct a detailed comparative analysis of  the p 55 particle forming 
capacity in different eucaryotic expression systems, we established a series of  
gag-gene constructs in the pUC vector system. In addit ion to the authentic 
p 55 gag gene (pUC8 p55), a mutant  form of the gag precursor lacking the NH2- 
terminal myristylation signal sequence was constructed altering the glycine 
residue at position 2 of the amino acid sequence to alanine (gly to ala, 
pUC8p55M-) .  The effect of  proteolytic processing on gag expression and 
particle formation was investigated by adding the protease (PR) coding sequence 
to the gag gene (/) in its natural  configuration (pUC8 p55 PR) and (ii) in frame 
to p 55 (pUC8 p55 PR-FS). Finally, we added the entire pol gene to the "p 55" 
and "p55 M-"  gene-constructs to reveal the proteolytic capacity of  the HIV- 
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1 protease in the complete 160 kDa gagpol polyprotein and to investigate the 
effect of myristylation on the processing of the precursor molecules. Using 
identical gag-gene constructs he level of HIV-core expression, proteolytic events 
and efficiency of particle formation could be determined and directly compared 
in different vector systems. Basic constructs and results described in the results 
are summarized in Fig. 1. 
Expression and biochemical analysis of p 55 and p 55-derived polypeptides 
in E. coti 
After subcloning of the gag-gene constructs into the ATG-vector pTRC 99, 
recombinant proteins were expressed in E. coli (Fig. 1). Immunoblot analysis 
using different p 24 and p 17 specific monoclonal antibodies reve, aled that all 
bacterial clones except pTRC p55 PR-FS expressed the authentic p 55 kDa gag 
precursor. Significant, but not complete processing was observed in lysates of 
p55 PR-, p55 Pol- and p55 M-  Pol-recombinant bacteria (data not shown). Re- 
verse transcriptase activity was measured in both bacterial clones, containing 
the entire polymerase gene (p55 Pol; p55 M-  Pol). 
In contrast, complete processing of the 65kDa p55PR precursor was 
achieved expressing the PR-gene in frame with the gag gene (p%RCp55PR- 
FS). The p 24/25 cleavage products were clearly visible in a SDS-PAGE stained 
with coomassie brilliant blue and could easily be detected by ,conventional 
Western blot analysis using p 24 specific monoclonal antibodies. Further de- 
tection of p 17 and the protease (9 kDa) by a monoclonal ntibody directed to 
p 17 and a monospecific peptide serum directed to protease quences confirmed 
the complete processing (data not shown). 
Alteration of the myristylation signal sequence did not affect p 55 expression 
in E. eoli. Neither sucrose gradient sedimentation analysis performed with 
culture supernatants of recombinant bacteria or cell extracts, nor electron mi- 
croscopy analysis performed with recombinant bacteria gave any 1hint on HIV- 
core particle formation in E.coli (data not shown). 
Expression and biochemical analys& of p 55 and related constructs 
by recombinant vaccinia virus 
Expression of the described constructs in CV-1 cells by recombinant vaccinia 
viruses was a fast approach to evaluate parameters involved in processing and 
core particle assembly (Fig. 1). The recombinant vaccinia viruses (v-p55, v- 
p55 M- ,  v-p55 PR, v-p55 PRFS, v-p55 Pol and v-p55 M - Pol) correspond ex- 
actly to the bacterial expression clones mentioned earlier. As hown by Western 
blot analysis (Fig. 2A), infection of CV-1 cells with v-p55, v-p55 M-  and v- 
p55 PR resulted in the expression of a 55 kDa and, to a smaller extent, of a 
41 kDa protein. Addition of the exact HIV-1 protease coding sequence (v- 
p55 PR) was not sufficient for detectable processing of p 55gag in CV-1 cells 
(Fig. 2A, lanes 5 and 12). The v-p55PR derived 41 kDa protein was clearly 
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Fig. 2. A Pattern of proteins ynthesized in CV-1 cells (2 x 105) after infection with different 
recombinant vaccinia viruses (t0 pfu/cell). Recombinant polypeptides were specifically de- 
tected by Western blot analysis using murine monoclonal ntibodies directed to p 17 (1 
and 2), p 24 (3-8) and by an AIDS patient serum pool (9-14). For negative control, CV- 
1 cells were infected by vTT wild type vaccinia virus (1, 8, and 9). To compare the influence 
of myristylation and proteolytic processing on p 55 expression, cells were infected byv-p55 
(3 and 10), v-p55 M- (4 and 11), v-p55 PR (2, 5, and 12), v-p55 Pol (6 and 13) and by v- 
p55 M- Pol (7 and 14). B Complete processing in the vaccinia systems is hown in CV-1 
cells infected with v-p55 PR-FS (3) as compared to CV-1 cells infected with v-p55 (2) and 
wild type vaccinia virus vTT. Molecular weight markers are indicated (kDa) 
recognized by a p 17 specific monoclonal antibody (Fig. 2 A, lane 2). For this 
reason, the production of p 41 was, at least partially, rather due to a suggested 
premature translational stop signal near the COOH-terminal part of the p 24 
coding sequence [93 than to HIV-mediated proteolytic events. Kinetical studies, 
following the infection over a period of 48 h did not show any specific, protease 
mediated processing, although the PR coding sequence was verified by DNA 
sequencing. In contrast o some previous reports [4, 363, we found significant 
processing when the entire pol reading frame was added to the gag gene. Un- 
processed p 55 gag, p 24/25 and different gag-processing intermediates with an 
estimated molecular weight of 40-41 kDa could now easily be detected in cell 
lysates (Fig. 2 A, lanes 6 and 7). Using a pool of sera from AIDS patients, p 17 
could be shown in addition to the polypeptides mentioned earlier (Fig. 2 A, 
lanes 13 and 14). As clearly demonstrated by analyzing extracts of v-p55 M-  Pol 
infected CV-1 cells, processing was not dependent on previous myristylation of 
the gag precursor molecule. For comparison expression of p55 PR-FS resulted 
in an almost efficient processing of the core precursor in the vaccinia expression 
system (Fig. 2 B). 
Sedimentation studies performed with culture supernatants and following 
Western blot analysis of the precipitated antigens gave identical results as 
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described for the cellular extracts in the case of v-p55-, v-p55 PR and v-p55 Pol 
infected cells. No antigen was detectable in culture supernatants ofcells infected 
with the myristylation deficient gag-constructs (v-p55 M- ,  v-p55 M-  Pol) and 
with v-p55 PR-FS (data not shown). 2 days following infection with recombinant 
vaccinia viruses supernatants of SW 480 cells were analyzed for reverse tran- 
scriptase (RT) activity as described in Materials and methods. RT activity could 
be precipitated only from the culture supernatant of v-p55 Pol infected cells, 
not from supernatants of cells infected with the analogous myristylation deficient 
form (v-p55 M-  Pol) (Fig. 3). These results gave first evidence (i) for the release 
of particulate aggregates, that (ii) need NHz-terminal myristylation for the 
budding from the infected cells into the culture supernatant. 
Requirements for budding of immature particles from mammalian cells 
infected by recombinant vaccinia virus 
Budding of p 55 core particles (100-160 nm in diameter) from the plasma mem- 
brane and release into the culture medium was detected by electron microscopy 
after infection of SW 480 cells with v-p55, v-p55 PR and v-p55 Pol (Figs. 1 and 
4). The lack of myristylation (v-p55 M- ,  v-p55 M-  Pol) at the NH2-termini 
apparently prevented targeting of the precursor polypeptides to the plasma 
membrane, confirming that myristylation of the polyprotein precursor is es- 
sential for its membrane localization and consecutive particle formation. As- 
sembly was also abolished when the HIV-protease was expressed in an artificial 
construct in frame with p 55 (v-p55 PR-FS; data not shown). Analysing v-p55 Pol 
infected cells morphologically, we clearly detected p 55 particle formation and 
budding of recombinant particles into the culture supernatant. However, using 
the conventional vaccinia expression system, the yield of recombinant immature 
core particles was not sufficient for preparative scale fermentation. 
The shape of p 55 gag particles produced by v-p55 and v-p55 Pol infected 
SW 480 cells is spherical, ovoidal or ellipsoid. The budding particles strongly 
resemble immature virus-like particles released from HIV- 1 infected cell cultures 
[5, 16]. There was no difference in a number of ultrathin sections detectable 
between v-p55 and v-p55 Pol derived core particles. Although we clearly found 
processing of the gag precursor in v-p55 Pol infected cells, we could neither find 











Fig. 3. Reverse transcriptase activ- 
ity profile of supernatants from 
uninfected SW 480 cells and from 
SW 480 cells infected with the re- 
combinant vaccinia viruses v-p55, 
v-p55 M-  Pol and v-p55 Pol 
126 R. Wagner et al. 
electron dense conical capsid known from mature HIV virions. The diameters 
of the budding structures show variations from 100 to 160 nm, whereas a mean 
diameter of 130 nm is most frequently observed. Vaccinia virus particles were 
larger (290 x 195 nm) and could be easily distinguished from p55gag particles 
(Fig. 4 B). Plasma membranes with a thickness of 6-7 nm (Fig. 4 A) formed 
spherical vesicles, the cytoplasmic site was coated by an electron-dense layer 
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with a thickness of 14-17 nm. Occasionally, this layer exhibited an additional, 
more electron dense border line (Fig. 4 E). The electron dense "15 nm" layer 
was typically interrupted at the site of budding (Fig. 4 E and F). Essentially, 
all p55 gag particles produced in the vaccinia system showed an electron-trans- 
lucent lumen which exhibited by far less granular components that the cyto- 
plasm. The content of fibrous material was similar to that of the cytoplasm. 
Expression and biochemical analysis of gag and related constructs 
in the baculovirus expression system 
To increase the yields of recombinant gag-particles and to analyze adverse 
effects of HIV protease mediated processing on particle formation, two of the 
basic constructs, pVL p55 and pVL p55 PR, were expressed by a recombinant 
baculovirus in insect cells. Massive production of recombinant p 55 was achieved 
by infection of Sf9 cells with b-p55 recombinant baculovirus (Fig. 5). It is 
noteworthy that unprocessed capsid precursor could be easily detected on im- 
munoblots analyzing infected cells and in culture supernatants harvested 5 days 
p.i. without prior concentration. In parallel to high expression, proteolytic 
digestion of the capsid precursor by cellular or AcMNPV specific proteases 
could be observed in cellular extracts. In contrast o the vaccinia expression 
system (v-p55 PR; Fig. 2 A, B), addition of the HIV-1 protease gene (b-p55 PR) 
resulted in complete processing of the p 55 precursor molecule in the baculovirus 
vector system. 
Budding of immature p55 gag particles following expression of the capsid 
precursor by recombinant baculovirus 
For analysis of the p 55 particle forming capacity, Sf9 insect cells were infected 
with b-p55 and, for comparison, with b-p55 PR. Infected cells were examined 
by electron microscopy (Fig. 6). 
Fig.4. Ultrathin sections of SW480 cells infected by v-p55 and v-p55Pol recombinant 
vaccinia virus illustrating the typical budding mechanism, p55gag precursor molecules 
accumulate, directed by amino-terminal myristylafion, t the cytoplasmic site of the plasma 
membrane (CM) forming electron dense hot spots (A). Proceeding aggregation of the capsid 
precursor forces the plasma membrane to form first hemispheral structures (B nd C), 
followed up by more spherical vesicular particles (D). Dissection of the immature p55 gag 
particles is managed by fusion of the plasma membrane. Appropriate section identifies the 
site of budding (open arrow), which is characterized by a local absence of the precursor 
molecule at the inner plasma membrane (E and F). The architecture and the budding 
mechanism of both, v-p55 (C and E) and v-p55 Pol (D and F) seems to be identical. An 
internal osmiophitic borderline (E, small arrow) can be visualized in very thin sections 
(35rim) as compared to 60nm sections (F). B Due to its size and shape (290 x 195rim), 
recombinant vaccinia virus (V) can be asily distinguished from the typical lentivirus-like 
budding core particles 
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Fig. 5. Western blot analysis showing recombi- 
nant proteins expressed in Sf9 cells (6 x 10 4) in- 
fected with recombinant baculovirus (5 pfu/cell). 
Recombinant proteins were detected by the p 24 
specific monoclonat antibody [41]. 1 Superna- 
tant (10 gl) of b-p55 infected Sf9 cells 5 days 
p.i., 2-4 extracts of Sf9 cells harvested 5 days 
after infection with b-p55 (2), b-p55 PR (3) and 
with AcMNPV wild type baculovirus (4). Mo-
lecular weight markers are indicated (kDa) 
B-p55 infected cells showed multiple lentivirus-like budding of particles with 
100-160 nm in diameter strongly resembling those budding from v-p55 and v- 
p55Pol infected cells at the cell membrane surface (Fig. 4). These structures 
were not detected in Sf9 cells infected by b-p55 PR and with wild type AcMNPV 
(data not shown). Assembly of the budding structures occurs at the cytoplasmic 
site of the plasma membrane. No particles or particulate structures were detected 
intracellularly. Production of the budding particles was abundant, leading to 
the release of single particles (Fig. 6 A) and to oligomeric aggregation (  = 2- 
4; Fig. 6 B) caused by incompletely dissociated complexes of budding structures 
or by monomeric particles fused immediately following the budding event. The 
structures dissociating from the cell membrane differed slightly in size and shape. 
Immature particles, produced in Sf9 cells showed an electron translucent 
center, which was covered by a dark, electron-dense ring and an outer 14-17 nm 
medium grey regular shell. The b-p55 derived particulate structures were sur- 
rounded by a 6-7 nm plasma membrane derived from the infected cell. Within 
the lumen of p55 gag particles formed by the baculovirus system, electron-dense 
granules with diameters of about 15-20 nm were observed (Fig. 6). These ex- 
tracellular p55 gag particles were similar to structures previously described as 
immature HIV-1 virions [5, 16]. Ultrathin section electron microscopy per- 
formed with b-p55 PR infected cells revealed adramatic decrease in p 55 particle 
formation, possibly due to the observed complete intracellular processing of 
the gag-precursor (Fig. 5), thus confirming that complete intracetlular p ocessing 
prevents core particle formation. 
In order to confirm p 55 particle formation and shedding of the particulate 
structures into the culture medium, we performed sucrose gradient sedimen- 
tation analyzing the culture supernatant of Sf9 cells harvested 1-5 days after 
infection with b-p55. Fractions collected from the gradient were analyzed by 
immunoblotting followed by densitometric s anning. Highest yields of budding 
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Fig. 6. Ultrathin section of Sf9 cells infected with a b-p55 recombinant baculovirus showing 
multiple budding of immature lentivirus like particles (A). The proposed mechanism of 
budding (B and C) is analogous to hat observed at the plasma membrane of SW 480 cells 
infected by the corresponding recombinant vaccinia virus (v-p55, Fig. 4). A Dramatic bud- 
ding in close vicinity obviously results in the formation of oligomeric and giant particles 
(asterisks). B Due to their od-like shape, recombinant baculoviruses (B) can be easily 
distinguished from the budding p 55 core particles 
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Fig. 7. Sucrose sedimentation analysis. Cells were infected with 10pfu/cell b-p55. Super-
natant was harvested 5 days p.i., precleared (3000 x g) in a Kontron centrifuge and layered 
onto a sucrose gradient (10-50%). After 2 h ofcentrifugation in a TST 41.14 rotor, sequential 
fractions were analyzed by Western blot analysis using the p 24 monoclonal antibody (B).
A The density of the serial fractions is indicated (11); antigenic peak fractions are labeled 
with a black bar. B Fractions containing particulate p 55 core structures are indicated (*) 
particles were obtained from supernatants harvested 5 days p.i. (Fig. 7). Spe- 
cifically detected bands of a higher molecular weight might represent oligo- 
merized p 55 precursor proteins. Signals of a reduced molecular weight might 
be due to a not specific degradation ofthe core precursor protein by cytoplasmic 
proteases randomly packaged into the core particles during the budding process. 
Negative staining and examination by electron microscope of the antigenic peak 
fractions demonstrated particulate core antigens at a sucrose density of 1.16- 
1.19 kg/1. Particulate structures were budding into the culture supernatant to 
an estimated concentration of 20-30mg/1. Peak fractions corresponded to a 
major 55 kDa protein species which was specifically detected in Western blots 
by monoclonal antibodies to p 24 (Fig. 7). In gradients performed with b-p55 PR 
derived culture supernatants, this peak fraction, containing particulate struc- 
tures was missing (data not shown). These data clearly confirmed that (/) p55 gag 
particles are budding from b-p55 infected Sf9 cells into the culture medium 
and that (i/) particle formation is considerably reduced by HIV-1 protease 
mediated processing as demonstrated in b-p55 PR infected Sf9 cells. 
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Fig. 8. p 24 specific IgG anti- 
body response induced in 2 rab- 
bits. Sera were taken 10 days 
following the injection of puri- 
fied p55 gag particles; 0 preim- 
mune sera; 1-3 antisera 
Immunogenicity of immature H IV  virus-like particles 
To demonstrate he immunogenicity of HIV-1 virus like particles, supernatants 
of b-p55 infected Sf9 cells were harvested and the immature particles were 
partially purified as described in Material and methods. Primary immunisation 
of two rabbits was performed using 67 ~tg of HIV-core antigen in complete 
Freund's adjuvant, followed by two booster injections with the same antigen 
dose in incomplete Freund's adjuvant f er 2 and 6 weeks. Ten days after each 
immunisation serum samples were tested for anti p 24 IgG production by a 
commercial ntigen specific ELISA (Behringwerke AG, Marburg, Federal Re- 
public of Germany). Antibody titers following the primary and booster injec- 
tions are shown in Fig. 8. The induced antibody titers were similar in both 
animals. The animals developed a strong anamnestic response following the 
first booster injection reaching titers in excess of 1/105. A further booster in- 
jection did not markedly increase the response. 
Discussion 
Intrinsic adjuvant properties of particulate antigens are indicated by successful 
and routine application of recombinant 22 nm hepatitis B virus (HBV) surface 
antigen (HBsAG) particles as a protective vaccine in humans [40]. Particle 
formation was also reported for the production of HBV core antigen in E. coli 
and for the capsid precursors of several retroviruses and retrovirus-like particles 
expressed in eucaryotic expression systems [1, 7, 17, 18]. Autologous and 
chimeric Ty-particles were producted in yeast cells and purified for the appli- 
cation in immunization experiments and clinical studies [27]. Vaccine mediated 
induction of an extensive humoral and cellular immune response to the HIV- 
1 core proteins might prove important in HIV vaccine development. The HIV- 
1 group specific antigen is highly conserved amongst different HIV-1 and HIV- 
2 isolates and was characterized in the past as an important arget of cell 
mediated [28, 42] and humoral immunity [30, 44]. We suggest that HIV-1 core 
particles themselves or products derived by adding additional sequence infor- 
mation are well suited as a safe and effective candidate vaccine. This study 
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aimed at investigating the parameters (e.g., HIV protease mediated processing 
or amino-terminal myristylation of the gag precursor) involved in budding of 
HIV- 1 core particles after expression of artificial gag-gene constructs invarious 
expression systems. In order to optimize HIV-1 core particle formation, different 
procaryotic and eucaryotic expression systems were compared. For optimal 
conditions of comparison, identical basic constructs were used for the produc- 
tion of different gag derived recombinant proteins. 
Core particle formation was not found in E. coli. One explanation could be 
the lack of posttranslational modifications which occur in authentic HIV in- 
fections [8, 41], but not in E. coli. As confirmed by our experiments analysing 
v-p55 and v-p55 M-  infected SW480 cells, glycine dependent NH2-terminal 
myristylation is essential for the budding of 100-160 nm immature p 55 particles 
(Fig. 1). In contrast to the nuclear localization of unmyristylated p 55 produced 
in the baculovirus system [6], we could not detected an accumulation of par- 
ticulate structures in the nucleus of v-p55 M-  infected SW480 cells. Interest- 
ingly, amino-terminal myristylation of the gagpol precursor is not an absolute 
prerequisite for consecutive processing. This is shown by the processing of the 
core precursor in v-p55M-Pol  infected CV-1 cells thus underlining major 
differences in the capsid morphogenesis between lentiviruses andtype D retro- 
viruses 1-8] (Fig. 2 A). 
Comparing both of the tested eucaryotic expression systems with respect to 
their p 55 particle forming capacity, we conclude that budding of immature gag 
particles is available from v-p55 infected mammalian cells as well as from Sf9 
insect cells infected with a p 55 recombinant baculovirus. Detailed morpholog- 
ical analysis of p55gag particles budding from infected SW480 and Sf9 cells 
by ultrathin section electron microscopy demonstrated a fine structure very 
similar to the immature gag particles detected in authentic HIV infections [5]. 
This proposes a common mechanism for assembly of immature particles at the 
cytoplasmic side of the plasma membrane (Figs. 4 and 6). However, we found 
dramatic differences in the amounts of budding of immature core particles 
between the expression systems tested. Corresponding to the fulminant expres- 
sion of p 55 in b-p55 infected cells, we found cluster-like accumulations of gag 
molecules at the inner cell membrane. A cluster of membrane bound gag pre- 
cursor molecules results in hotspots of budding particles (Fig. 6). Due to the 
abundant budding, a considerable part of the detected free particles produced 
from b-p55 infected insect cells is specified by oligomeric aggregates. In contrast, 
we find only small amounts of single, not oligomerized p 55 particles budding 
from the plasma membrane of v-p55 infected SW 480 cells, possibly due to the 
significantly weaker expression of the gag precursor in the vaccinia system. 
Based on densitometric analysis of immunoblots we found a 50 fold excess of 
gag-protein synthesis in the baculovirus ystem (b-p55) as compared to the 
production of the core precursor by recombinant vaccinia virus in mammalian 
cells (data not shown). According to the described existence of cellular myristyl 
moiety receptor molecules [32, 33], a reduced number of these receptors in the 
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tested mammalian cells might be responsible for the comparably low yield of 
p55 gag particles in the vaccinia virus system. Moreover, differences in growth 
conditions between Sf9 cells (28 °C) and SW480 cells (37 °C) might influence 
the membrane fluidity and consequently the formation of gag-particles. 
Addition of PR- or pol-coding sequences to the gag gene did not provide 
for the synthesis of particles that resemble naturally occurring mature capsid 
structures including the typical conical p 24 core [5, 16]. Interestingly, addition 
of the exact PR coding sequence to the gag gene in its original reading frame 
(v-p55 PR) was not sufficient o induce significant processing of the core pre- 
cursor in the vaccinia virus system (Fig. 2 A). This unexpected result is in agree- 
ment with findings of Shioda et al. [36]), but is in clear contrast o the observed 
complete processing of the gag-precursor in extracts of b-p55 PR infected Sf9 
cells (Fig. 5). Addition of the entire pol coding sequence to the gag gene and 
expression by vaccinia viruses (v-p55 Pol, v-p55 M-  Pol) resulted in a significant, 
but not complete processing of the polyprotein precursors, that resembled the 
authentic situation in HIV-infected H 9 cells. This strongly indicates the in- 
volvement of regions COOH-terminal from the actual PR-domain in efficient 
formation of enzymatically active protease dimers (Fig. 2 A). In contrast, com- 
plete processing of the gag precursor shown by b-p55 PR infected Sf9 cells 
(Fig. 5, lane 3) and by v-p55 PR-FS infected mammalian cells (Fig. 2 B) dras- 
tically reduced core particle formation (Fig. 1). We propose, that dimerization 
of monomeric PR-domains, suggested to be necessary for complete processing 
of precursor molecules, which is not found in HIV infected cells, :requires high 
intracellular concentrations of the gag PR-readthrough proteins within the cell. 
Such concentrations possibly are only reached in artificial expression systems 
like, e.g., b-p55 PR infected Sf9 cells or in CV-1 cells infected with the v-p55 PR- 
FS vaccinia virus. 
However, even partial processing did not finish the core maturation process. 
As demonstrated in a number of ultrathin sections, we could only find core 
particles budding from the plasma membrane described as immature virus 
particles by Gelderblom et al. [5]. These results clearly indicate, that the syn- 
thesis of mature capsids in artificial expression systems can not be achieved by 
simple addition of the protease or polymerase gene to the gag open reading 
frame. Recent publications described the synthesis of gag particles containing 
an electron dense core and HIV-RNA using a vaccinia driven expression system 
[11] and in stable transfection experiments [12]. A common feature of both 
experiments i the use of DNA constructs including, in addition to the PR 
coding sequence, an RNA packaging signal, located only few basepairs upstream 
of the p 55 coding sequence [22]. In contrast, using gag sequences lacking the 
packaging signal sequence, we could not find RNA packaged in our gag particle 
preparations in Nothern blot analysis (data not shown). Taken together, these 
observations suggest, that viral HIV RNA containing the packaging signal is 
at least partially involved in the capsid maturation process. 
Immunological evaluation of immature gag particles purified from b-p55 
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infected Sf9 cells showed a high immunogenicity n rabbits. Preliminary results, 
using p 55 recombinant vaccinia viruses (v-p55) for immunisation of rabbits 
gave significantly lower titers of specific antibodies suggesting that recombinant 
core particles were more immunogenic than the vaccinia constructs (unpubl. 
data). Taken together, we conclude that empty immature p55gag particles 
lacking viral RNA and produced by recombinant baculovirus are well suited 
as a noninfectious vaccine component. Parallel studies try to identify regions 
in the gag precursor that can be exchanged by immunologically relevant epitopes 
encoded by other HIV-1 genes without disturbing the p 55 particle forming 
capacity. This approach aimed at extending the immunological spectrum of the 
p55 gag derived particles by inserting cytotoxic and helper T-cell determinants 
as well as neutralizing epitopes uch as the gp 120 principal neutralizing deter- 
minant V3 (PND). Adverse side effects such as gp 120 dependent, antibody 
mediated enhancement of infection or the induction of immune suppresive 
effects would be excluded. The safety of engineered particulate vaccines would 
be guaranteed by the lack of viral LTR elements and primer binding sites. 
Moreover, deletion of the RNA packaging signal, the lack of enzymes (PR, 
RT, IN) and essential regulatory proteins (Tat, Rev, Vif) important for a possible 
recombination to infectious particles would enhance the safety of such a can- 
didate vaccine. 
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